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OBJECTIVE: Hospitalization and inpatient charge comparisons
for bipolar and manic patients receiving atypical and conven-
tional antipsychotics. METHODS: Analysis of a claims database
(1999–2003) representing 50 million US insured patients 
identiﬁed 12,835 treatment episodes of monotherapy for bipolar
and manic disorders with atypicals (risperidone, olanzapine, 
quetiapine, ziprasidone) and conventionals (haloperidol, 
perphenazine, thioridazine, thiothixene). Hazard ratios (HR) for
hospitalization risks were estimated with Cox regression adjust-
ing for patient characteristics. Inpatient charges were based on
these estimates and estimated hospital stays. RESULTS: Risperi-
done and olanzapine had signiﬁcantly (P < 0.05) higher risks of
hospitalization than quetiapine (HR 1.185 and 1.187, respec-
tively) and trended (P < 0.10) toward higher risks than ziprasi-
done (HR 1.443 and 1.447, respectively), translating into higher
inpatient charges of $194–$389 per patient per year. On com-
paring the atypicals in manic rapid cyclers (a high hospitaliza-
tion subgroup), risperidone had a signiﬁcantly (P < 0.05) higher
risk of hospitalization than olanzapine (HR = 3.309) and olan-
zapine trended (P < 0.10) toward longer stays than quetiapine
(7.56 days longer), both translating into higher inpatient charges.
CONCLUSION: In treating bipolar and manic disorders, risperi-
done and olanzapine may have higher risks of hospitalization
than quetiapine. In treating manic rapid cyclers, olanzapine may
have a lower risk of hospitalization than risperidone, but longer
stays than quetiapine.
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OBJECTIVES: To determine the prevalence of patients with
bipolar disorder (BD) and compare their annual health care costs
to patients with other mental health disorders, in a large United
States managed care organization. METHODS: This was a ret-
rospective claims analysis of approximately 1.4 million com-
mercial health plan members with mental health beneﬁts. Adults
with a primary or secondary diagnosis of a mental health disor-
der in 2002 were identiﬁed and the prevalence of BD calculated.
Those continuously enrolled throughout 2003 (follow-up
period) were stratiﬁed to one of two cohorts: “BD” (Bipolar 
Disorder) or “OMHD” (Other Mental Health Disorder). Patient
demographics, pharmacological treatments, and health care
charges were compared between cohorts, adjusting for potential
confounding factors of age, gender, and comorbidity. RESULTS:
During 2002, there were 6581 patients (mean age 40.3 years;
65.7% female) with BD, yielding an overall prevalence rate of
4.68 per 1000 members. Among the 64,434 continuously
enrolled mental disorder patients in 2003, 3,043 (4.7%) were
classiﬁed as “BD” and 61,391 (95.3%) were classiﬁed as
“OMHD”. Patients in the “BD” group were younger (41.7 vs.
43.0 years; p < 0.0001) with higher Charlson comorbidity index
(0.56 vs. 0.47; p < 0.0001) compared to the “OMHD” group.
Less than half (38.3%) of “BD” patients received a mood sta-
bilizer (lithium, valproate, or carbamazepine) and 20.0%
received no psychotropic medication. Adjusted pharmacy,
medical, and total health care charges were higher in the “BD”
group compared to “OMHD”: $2641 vs. $1071, $13,419 vs.
$8422, and $16,059 vs. $9493 respectively (p < 0.0001 for all
three comparisons). CONCLUSIONS: Compared to the national
prevalence rate of 1%, BD may be under-diagnosed, and phar-
macologic therapy underutilized within managed care. Patients
with BD incurred greater health care charges compared to other
mental health disorders. Efforts aimed at improving diagnosis
and treatment of BD may optimize care and cost of managing
this patient population.
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OBJECTIVES: Existing research offers little empirical evidence
to support national practice guidelines about antidepressant use
in patients with bipolar disorder. This study assessed the clinical
and economic impact of second-generation antidepressant use
for bipolar depressed adult patients. METHODS: Bipolar disor-
der subjects were identiﬁed with a new depressive episode in a
national managed-care plan between January, 1998 and Decem-
ber, 2002. In total, 3737 patients were deﬁned with the index of
interested medication initiation and at least three-months pre-
index and 12-month post-index continuous enrollments. Logit
model with a difference-in-difference approach was employed to
identify the relationship between treatment types (antidepressant
monotherapy, mood stabilizer monotherapy, and antidepressant-
mood stabilizer combination therapy) and the probability of
mania-related visits. In addition, negative binomial model and
log-transformed OLS model were used to predict number of
depression-related visits and health care costs respectively.
RESULTS: Probability of mania-related visits increased signiﬁ-
cantly from pre-index to post-index period with odds ratio 2.40
(95% CI: 1.52–3.79) for antidepressant monotherapy compared
to mood stabilizer monotherapy, controlling for time ﬁxed-effect,
demographics, clinical-related and health-related variables.
However no signiﬁcant difference was identiﬁed between com-
bination therapy and mood stabilizer monotherapy. Patients 
with antidepressant monotherapy and combination therapy had
signiﬁcantly lower incidence rate ratios of 0.68 (95% CI:
0.56–0.82) and 0.65 (95% CI: 0.52–0.81) respectively for
depression-related visits, but signiﬁcantly higher bipolar-related
costs (232% and 72% respectively) compared to patients with
mood stabilizer monotherapy. CONCLUSIONS: This study adds
to the literature of bipolar depression treatment by providing
empirical evidence at the national level to support the current
practice guidelines. Second-generation antidepressant monother-
apy indicated a risk of induced manic-switching, which can be
costly in terms of overall health care resources. Since the safety
and efﬁcacy of antidepressants in bipolar disorder have not been
ﬁrmly established, medical practitioners and policy makers
should take precautions regarding the appropriate use of new
antidepressants.
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OBJECTIVES: To assess the clinical outcomes of modern
second-generation antidepressant medication use in bipolar dis-
order, with a focus on the risk of induced manic-switching for
adult patients with bipolar depression. METHODS: Bipolar dis-
order subjects were identiﬁed with a new depressive episode in
a national managed care plan between January, 1998 and
December, 2002. A case-control study design was applied for
which cases and controls were deﬁned by whether having mania-
related visits in the 12-months continuous enrollment after
